Purchase Description.pdf

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose: National Institute on Aging (NIA) requires state-of-art assay kits for quantification of serum/plasma of abeta42, abeta40, and pTau 217 using Lumipulse assays on the Lumipulse G1200 instrument. These biomarkers will be assayed using stored specimens from participants in the Baltimore Longitudinal Study of Aging (BLSA).

2. Background Information and Objective: Evidence from autosomal dominant

Alzheimer’s disease (AD) research suggests that soluble forms of phosphorylated tau may have downstream effects on neurodegenerative processes and cognitive decline. Recent data suggest that pTau217 may be particularly sensitive to the development of brain amyloid. The purpose of this procurement is to perform assays for biomarkers of AD (ABeta, pTau) in longitudinal data from participants in the BLSA who have scores on the phenotypic metric of aging index or proteomics data. These data will be used by investigators in the Laboratory of Behavioral Neuroscience and Translational Gerontology Branch to leverage the wealth of available neuroimaging, cognitive, and clinical data in the BLSA. Specifically measures of ABeta and pTau217 will be used to stratify participants to determine the likelihood that participants are in a preclinical phase of AD. These measures will also be used continuously alone and in combination with biomarkers of inflammation and neuronal injury to further understand the causes of cognitive and brain changes in healthy individuals and those with a variety of comorbidities. This project requires the use of high throughput equipment and sensitive assays for the identification of these biomarkers and for continuity of research, must be performed in a similar way to prior assays in serum/plasma from BLSA participants and using approaches that have been broadly selected for use in Alzheimer’s Disease Research Centers. These biomarkers will provide important insights into the biological underpinnings of cognitive impairment and AD/ADRD years before any symptoms would be apparent.

New insights may lead to early identification of those most likely to show cognitive decline, as well as novel treatments to help prevent or delay AD/ADRD.

3. Generic Name of Product: abeta42, abeta40, and pTau 217 Lumipulse assays

4. Purchase Description: Manufacturer’s Name: Fujirebio

5. Salient characteristics:

Contractor shall provide the NIA/LBN with abeta42, abeta40, and pTau 217 Lumipulse assay kits, as well as controls:

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

• IRC Plsama BA1-42 3x14

• IRC Plsama BA1-40 3x14

• IRC Plasma pTau217 3x14

Cals

• Plasma BA1-42 1x5

• Plasma BA1-40 1x5

• Plasma pTau217 1x5

Controls

• Plasma BA1-42 2x2

• Plasma pTau217 2x2

6. Quantity: 7182

7. Delivery Date: Within 120 days after after contractor receipt of award